<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine a possible role of aberrant somatic hypermutation (ASHM) in the pathogenesis of thyroid <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (TL), mutational status of genes affected by ASHM, including c-MYC, PIM-1, PAX-5 and RhoH/<z:chebi fb="6" ids="52444">TTF</z:chebi>, was analyzed </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> specimens from 33 patients with thyroid B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 14 with <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:hpo ids='HP_0100646'>thyroiditis</z:hpo> (CLTH), an autoimmune <z:hpo ids='HP_0100646'>thyroiditis</z:hpo> known to provide a basis for TL development, was examined </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations of at least one of these genes was detected in 16 of 33 (48.5%) patients with TL and in 2 of 14 (14.3%) CLTH </plain></SENT>
<SENT sid="3" pm="."><plain>Occurrence of ASHM in PIM-1, RhoH/<z:chebi fb="6" ids="52444">TTF</z:chebi>, and c-MYC was a constant finding in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) (<z:hpo ids='HP_0000001'>all</z:hpo> of 11 cases) but not so frequent in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) (4 (33.3%) of 12 cases) and Marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e>) (1 (10.0%) of 10 cases) </plain></SENT>
<SENT sid="4" pm="."><plain>ASHM activity is ongoing in most of FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> because intraclonal variants were found </plain></SENT>
<SENT sid="5" pm="."><plain>FL was also unique in its lower expression level of activation-induced <z:chebi fb="0" ids="17562">cytidine</z:chebi> deaminase, a main player in DNA-modifying processes during SHM, compare to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e> </plain></SENT>
</text></document>